Pfizer Inc. has reported its second-quarter 2025 financial results, showcasing a solid performance with a total revenue of $14.7 billion, marking a 10% increase from the $13.3 billion recorded in the same quarter of 2024. This growth was primarily driven by increased revenues from key products such as the Vyndaqel family, Comirnaty, Paxlovid, Padcev, and Eliquis, despite facing challenges from higher manufacturer discounts linked to the IRA Medicare Part D Redesign. The company's Adjusted Cost of Sales as a percentage of revenues rose to 23.9%, up by 3.1 percentage points from 20.8% in the previous year. This increase was largely attributed to the absence of a one-time favorable adjustment to accrued royalties that benefited the second quarter of 2024. Additionally, Pfizer reported a decrease in Adjusted Selling, Informational and Administrative (SI&A) Expenses, which amounted to $3.4 billion, an 8% decrease from the $3.7 billion in the second quarter of 2024. This reduction was largely due to targeted investments and continued productivity enhancements, leading to reduced marketing and promotional expenditures across various products and decreased spending in corporate enabling functions. The company remains on track to deliver approximately $7.7 billion in anticipated overall savings from previously announced cost improvement initiatives. No specific guidance or future outlook was provided in the report.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief on August 05, 2025, and is solely responsible for the information contained therein.
Comments